|
Avidity Biosciences, Inc. (ARN) Valoración de DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Avidity Biosciences, Inc. (RNA) Bundle
¡Descubra el verdadero potencial de la avidez Biosciences, Inc. (ARN) con nuestra calculadora DCF avanzada! Ajuste los supuestos clave, explore varios escenarios y evalúe cómo las modificaciones influyen en la valoración de Avidity Biosciences, Inc. (ARN), todo dentro de una plantilla integral de Excel.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.3 | 6.8 | 9.3 | 9.2 | 9.6 | 12.9 | 17.4 | 23.5 | 31.7 | 42.9 |
| Revenue Growth, % | 0 | 192.67 | 37.41 | -1.09 | 3.64 | 34.99 | 34.99 | 34.99 | 34.99 | 34.99 |
| EBITDA | -16.8 | -43.8 | -117.4 | -177.5 | -233.5 | -12.9 | -17.4 | -23.5 | -31.7 | -42.9 |
| EBITDA, % | -722.29 | -644.95 | -1258.97 | -1924.61 | -2442.44 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | .6 | .4 | .6 | 1.4 | 2.1 | 1.9 | 2.6 | 3.5 | 4.8 | 6.4 |
| Depreciation, % | 25.74 | 5.5 | 6.85 | 15.04 | 21.98 | 15.02 | 15.02 | 15.02 | 15.02 | 15.02 |
| EBIT | -17.3 | -44.1 | -118.1 | -178.9 | -235.6 | -12.9 | -17.4 | -23.5 | -31.7 | -42.9 |
| EBIT, % | -748.04 | -650.45 | -1265.83 | -1939.65 | -2464.41 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 94.6 | 328.1 | 405.5 | 610.7 | 595.4 | 12.9 | 17.4 | 23.5 | 31.7 | 42.9 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | 1.2 | .9 | .0 | 1.1 | 1.0 | 1.4 | 1.8 | 2.5 | 3.3 |
| Account Receivables, % | 0 | 17.68 | 9.65 | 0 | 11.56 | 7.78 | 7.78 | 7.78 | 7.78 | 7.78 |
| Inventories | .0 | -1.2 | -.9 | .0 | .0 | -.7 | -1.0 | -1.3 | -1.7 | -2.3 |
| Inventories, % | 0.000043122035 | -17.68 | -9.65 | 0.000010841284 | 0 | -5.47 | -5.47 | -5.47 | -5.47 | -5.47 |
| Accounts Payable | 2.3 | 7.7 | 2.8 | 4.6 | 8.8 | 9.6 | 13.0 | 17.5 | 23.6 | 31.9 |
| Accounts Payable, % | 99.53 | 114.12 | 30.09 | 50.27 | 92.14 | 74.41 | 74.41 | 74.41 | 74.41 | 74.41 |
| Capital Expenditure | -.2 | -1.1 | -3.7 | -2.8 | -4.2 | -3.6 | -4.9 | -6.6 | -9.0 | -12.1 |
| Capital Expenditure, % | -10.13 | -16.09 | -40.1 | -30.6 | -44.23 | -28.23 | -28.23 | -28.23 | -28.23 | -28.23 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -22.5 | -43.8 | -117.4 | -173.9 | -235.6 | -12.8 | -17.3 | -23.3 | -31.5 | -42.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -19.9 | -39.1 | -125.5 | -173.5 | -234.7 | -12.9 | -16.3 | -22.0 | -29.7 | -40.1 |
| WACC, % | 8.72 | 8.72 | 8.72 | 8.72 | 8.72 | 8.72 | 8.72 | 8.72 | 8.72 | 8.72 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -90.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -41 | |||||||||
| Terminal Value | -610 | |||||||||
| Present Terminal Value | -401 | |||||||||
| Enterprise Value | -492 | |||||||||
| Net Debt | -175 | |||||||||
| Equity Value | -317 | |||||||||
| Diluted Shares Outstanding, MM | 73 | |||||||||
| Equity Value Per Share | -4.34 |
What You Will Get
- Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real Avidity Biosciences (RNA) financials.
- Real-World Data: Historical data and forward-looking estimates (as indicated in the highlighted cells).
- Forecast Flexibility: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Automatic Calculations: Instantly observe the effect of your inputs on Avidity Biosciences' valuation.
- Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.
Key Features
- Customizable Research Parameters: Adjust essential inputs such as target market size, R&D expenses, and clinical trial timelines.
- Instant Valuation Metrics: Quickly computes intrinsic value, NPV, and other financial indicators.
- High-Precision Accuracy: Leverages Avidity Biosciences' (RNA) actual financial data for dependable valuation results.
- Simplified Scenario Testing: Easily evaluate various hypotheses and analyze different outcomes.
- Efficiency Booster: Streamlines the process, removing the need for intricate valuation models from the ground up.
How It Works
- Step 1: Download the prebuilt Excel template with Avidity Biosciences, Inc.'s (RNA) data included.
- Step 2: Explore the pre-filled sheets and familiarize yourself with the key metrics.
- Step 3: Update forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly view recalculated results, including Avidity Biosciences, Inc.'s (RNA) intrinsic value.
- Step 5: Make informed investment decisions or generate reports using the outputs.
Why Choose Avidity Biosciences, Inc. (RNA)?
- Innovative Solutions: Cutting-edge RNA-targeted therapies designed to address unmet medical needs.
- Proven Expertise: A team of industry veterans dedicated to advancing RNA science and technology.
- Robust Pipeline: A diverse portfolio of candidates in various stages of development for multiple indications.
- Commitment to Quality: Adherence to rigorous standards ensures the highest level of safety and efficacy.
- Collaborative Approach: Partnerships with leading organizations to enhance research and development efforts.
Who Should Use This Product?
- Biotech Investors: Develop comprehensive and accurate valuation models for assessing Avidity Biosciences, Inc. (RNA) stock.
- Corporate Strategy Teams: Evaluate valuation scenarios to inform strategic decisions within the biotech sector.
- Consultants and Advisors: Deliver precise valuation insights and recommendations for clients interested in Avidity Biosciences, Inc. (RNA).
- Students and Educators: Utilize real-time data to enhance learning and practice in financial modeling within the biotech industry.
- Healthcare Analysts: Gain insights into how innovative biotech companies like Avidity Biosciences, Inc. (RNA) are valued in the market.
What the Template Contains
- Pre-Filled Data: Includes Avidity Biosciences, Inc.'s historical financials and forecasts.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
- Key Financial Ratios: Analyze Avidity Biosciences, Inc.'s profitability, efficiency, and leverage.
- Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
- Clear Dashboard: Charts and tables summarizing key valuation results.